Statements (40)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
1983 |
| gptkbp:ATCCode |
gptkb:A02BA02
|
| gptkbp:availableOn |
gptkb:sugar
gptkb:tablet injection |
| gptkbp:brand |
gptkb:Zinetac
gptkb:ranitidine gptkb:Acidil Ranitic |
| gptkbp:chemicalFormula |
C13H22N4O3S
|
| gptkbp:contraindication |
allergy to ranitidine
|
| gptkbp:drugClass |
H2 receptor antagonist
|
| gptkbp:eliminationHalfLife |
2.5-3 hours
|
| gptkbp:excretion |
gptkb:kidney
|
| gptkbp:genericAvailable |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zantac
|
| gptkbp:legalStatus |
withdrawn in US
withdrawn in EU |
| gptkbp:manufacturer |
Glaxo (now GSK)
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
diarrhea constipation headache |
| gptkbp:usedFor |
heartburn
acid reflux stomach ulcers |
| gptkbp:withdrawn |
2020
yes NDMA contamination |
| gptkbp:bfsParent |
gptkb:CHEMBL1487
gptkb:GLAXO gptkb:ranitidine gptkb:Glaxo_Wellcome |
| gptkbp:bfsLayer |
7
|